-

Minze Health Announces Collaboration with Medtronic to Support Patients with Overactive Bladder in EMEA

Patients with bladder control symptoms who receive a Medtronic Sacral Neuromodulation Device will now have access to the Minze Diary Pod

ANTWERP, Belgium--(BUSINESS WIRE)--Minze Health, a digital health company, today announced a three-year agreement with Medtronic, a global leader in healthcare technology, to commercialize the Minze Diary Pod across the EMEA region. The agreement will expand the support services available for patients with bladder control symptoms, known as Overactive Bladder (OAB), undergoing Sacral Neuromodulation (SNM) therapy with a Medtronic InterStim™ system.

“Empowering patients and clinicians with smarter, data-driven overactive bladder care.”

Share

Under this partnership, the Minze Diary Pod – an automated bladder diary solution – will be offered as part of the SNM care pathway, enabling clinicians and patients to gather richer, more objective data during diagnosis and follow-up. This addition supports earlier and more confident decisions to initiate SNM therapy and provides valuable post-implantation insights on therapy effectiveness.

The Minze Diary Pod allows patients to seamlessly track urinary behaviour at home, without the burden of paper diaries, improving compliance and data reliability. Clinicians benefit from automated data interpretation and a secure digital platform for remote monitoring and decision support.

“We’re proud to collaborate with Medtronic to bring our technology to more patients and providers across Europe and beyond,” said Thomas Moore, CEO of Minze Health. “Together, we’re transforming the way urological symptoms are assessed, treated and monitored — with digital tools that enable precision, efficiency and patient engagement.”

About Minze Health

Minze Health is transforming urology by combining accurate at-home diagnostics, remote monitoring, and digital therapeutics into a single, scalable platform. With CE mark and 510(k) exemptions, Minze’s ecosystem supports early diagnosis and personalized care for conditions like BPH and OAB—empowering patients and relieving pressure on overburdened urology systems. For more information, visit www.minzehealth.com.

Contacts

Media Contact:
Thomas Moore
CEO, Minze Health
Email: tom.moore@minzehealth.com
Phone: +1 763.258.9039

Minze Health


Release Summary
Minze Health partners with Medtronic to integrate its automated bladder diary, Minze Diary Pod, into Sacral Neuromodulation care for OAB patients.
Release Versions

Contacts

Media Contact:
Thomas Moore
CEO, Minze Health
Email: tom.moore@minzehealth.com
Phone: +1 763.258.9039

More News From Minze Health

Minze Health and Apogepha Enter Strategic Collaboration to Develop Digital Therapeutic for Male LUTS

ANTWERP, Belgium & DRESDEN, Germany--(BUSINESS WIRE)--Minze Health, a leader in digital diagnostics and therapeutics for urology, and Apogepha Arzneimittel GmbH (“Apogepha”), a family-owned specialty pharmaceutical company focused on urology, today announced a joint development agreement to co-develop and commercialize a prescription digital therapeutic (DTx) for men suffering from Lower Urinary Tract Symptoms (LUTS). This partnership merges Minze’s evidence-based digital health platform and in...

Minze Health Appoints Thomas Moore as President and Chief Executive Officer

ANTWERP, Belgium & MINNEAPOLIS--(BUSINESS WIRE)--Minze Health, a leader in digital diagnostics and therapeutics for urology, announced today that Thomas Moore has been appointed President and Chief Executive Officer, effective immediately. Moore brings over two decades of commercial leadership in medtech and a proven track record of driving growth, reimbursement, and global market expansion across the U.S. and Europe. Prior to joining Minze, Moore served as Chief Commercial Officer at GT Medica...

Minze Health Raises US$ 5.3 Million in Funding to Develop Prescription Digital Therapeutics and Drive Commercialization in the US Market

ANTWERP, Belgium--(BUSINESS WIRE)--Minze Health, a pioneer in digital health solutions for urology, has successfully secured USD 5.3 million in a funding round led by its existing investors White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. The funding round also saw the participation of a new investor, imec.istart future fund, marking a significant step forward for the company’s growth and innovation. The proceeds will be used to further develop and bring to mar...
Back to Newsroom